| Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy AJ Muller, JB DuHadaway, PS Donover, E Sutanto-Ward, GC Prendergast Nature medicine 11 (3), 312-319, 2005 | 1265 | 2005 |
| Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain AR Ferré-D'Amaré, GC Prendergast, EB Ziff, SK Burley Nature 363 (6424), 38-45, 1993 | 946 | 1993 |
| BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression DE Jensen, M Proctor, ST Marquis, HP Gardner, SI Ha, LA Chodosh, ... Oncogene 16 (9), 1097-1112, 1998 | 896 | 1998 |
| Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region GC Prendergast, EB Ziff Science 251 (4990), 186-189, 1991 | 777 | 1991 |
| Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation GC Prendergast, D Lawe, EB Ziff Cell 65 (3), 395-407, 1991 | 740 | 1991 |
| Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses DY Hou, AJ Muller, MD Sharma, J DuHadaway, T Banerjee, M Johnson, ... Cancer research 67 (2), 792-801, 2007 | 729 | 2007 |
| Aryl hydrocarbon receptor control of a disease tolerance defence pathway A Bessede, M Gargaro, MT Pallotta, D Matino, G Servillo, C Brunacci, ... Nature 511 (7508), 184-190, 2014 | 707 | 2014 |
| Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan R Metz, JB DuHadaway, U Kamasani, L Laury-Kleintop, AJ Muller, ... Cancer research 67 (15), 7082-7087, 2007 | 614 | 2007 |
| Mechanisms of apoptosis by c-Myc GC Prendergast Oncogene 18 (19), 2967-2987, 1999 | 607 | 1999 |
| Classification of current anticancer immunotherapies L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ... Oncotarget 5 (24), 12472, 2014 | 585 | 2014 |
| Discovery of IDO1 inhibitors: from bench to bedside GC Prendergast, WP Malachowski, JB DuHadaway, AJ Muller Cancer research 77 (24), 6795-6811, 2017 | 538 | 2017 |
| Indoleamine 2, 3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer GC Prendergast, C Smith, S Thomas, L Mandik-Nayak, L Laury-Kleintop, ... Cancer immunology, immunotherapy 63, 721-735, 2014 | 528 | 2014 |
| Indoleamine 2, 3‐dioxygenase in T‐cell tolerance and tumoral immune escape JB Katz, AJ Muller, GC Prendergast Immunological reviews 222 (1), 206-221, 2008 | 520 | 2008 |
| Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models N Takahashi, L Duprez, S Grootjans, A Cauwels, W Nerinckx, ... Cell death & disease 3 (11), e437-e437, 2012 | 500 | 2012 |
| The polyproline region of p53 is required to activate apoptosis but not growth arrest D Sakamuro, P Sabbatini, E White, GC Prendergast Oncogene 15 (8), 887-898, 1997 | 488 | 1997 |
| BIN1 is a novel MYC–interacting protein with features of a tumour suppressor D Sakamuro, KJ Elliott, R Wechsler-Reya, GC Prendergast Nature genetics 14 (1), 69-77, 1996 | 471 | 1996 |
| Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. P Carmeliet, L Kieckens, L Schoonjans, B Ream, A Van Nuffelen, ... The Journal of clinical investigation 92 (6), 2746-2755, 1993 | 446 | 1993 |
| Immune escape as a fundamental trait of cancer: focus on IDO GC Prendergast Oncogene 27 (28), 3889-3900, 2008 | 445 | 2008 |
| c‐Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. LH Li, C Nerlov, G Prendergast, D MacGregor, EB Ziff The EMBO journal 13 (17), 4070-4079, 1994 | 430 | 1994 |
| IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan R Metz, S Rust, JB DuHadaway, MR Mautino, DH Munn, NN Vahanian, ... Oncoimmunology 1 (9), 1460-1468, 2012 | 417 | 2012 |
Alexander J. MullerAssociate Professor, Lankenau Institute for Medical Research在 mlhs.org 的電子郵件地址已通過驗證